Abbott/AstraZeneca's Certriad Bounced By FDA; ACCORD Is The Likely Culprit
This article was originally published in Pharmaceutical Approvals Monthly
Abbott and AstraZeneca aren't providing any details about why the FDA issued a "complete response" letter for their cholesterol-lowering combo drug Certriad (rosuvastatin/fenofibric acid delayed release). But given that the fixed-dose combination pill combines two already marketed drugs - AstraZeneca's statin Crestor and Abbott's triglyceride-lowering medication TriLipix - it's likely the agency's concerns have more to do with efficacy than safety
You may also be interested in...
Report from ACC: Experts advise reading the fine print of the study - which failed to show an overall outcome benefit - as sub-group analysis shows highest-risk patients might benefit.
AstraZeneca and Abbott announce co-promotion agreement for TriLipix ahead of an FDA decision on a jointly-developed investigational Crestor/TriLipix compound.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011